tirzepatide irregular periods Does Cause Spotting? Side Effects Explained Why Your Period Changes on
Description
Socorro, NM
In patients with type 2 diabetes and high cardiovascularrisk, clinical trials have shown that GLP-1 receptor agonistsreduce the incidence of major adverse cardiovascular events.The effect of tirzepatide a dual incretin agonist of theGLP-1 and GIP receptors on cardiovascular outcomes isuncertain. In theSURPASS-CVOTtrial, patients40 years of age or older with type 2 diabetes, a BMIof at least 25, and atherosclerotic cardiovascular disease wererandomly assigned to receive a weekly subcutaneous injectionof tirzepatide (up to 15 mg) or dulaglutide (1.5 mg), a GLP-1receptor agonist that has been shown to reduce the incidenceof cardiovascular events
Book a consultation with our team at Klinik Sentosa to find out if Mounjaro is right for you
Im not sponsored, and no one paid me to say this
They advise patients experiencing sudden vision loss or rapidly worsening eyesight to seek medical attention immediately
